drug:orforglipron
Updates from MariTide & Orforglipron research
MariTide and Orfoglipron updates from the ADA 85th Science Sessions conference in June, with the key results that were announced.
drug:orforglipron
MariTide and Orfoglipron updates from the ADA 85th Science Sessions conference in June, with the key results that were announced.
chemical:semaglutide
Novo Nordisk and HIMS end their partnership that brought cheaper Wegovy (Semaglutide) to customers of HIMS.
 
            category:news
We deep dive on Bimagrumab, a muscle-preserving booster to GLP1 receptor agonists like Ozempic, Wegovy, Mounjaro, Zepbound and others.
 
            company:novo-nordisk
Novo Nordisk's patent protections lapse early after forgetting to pay a small fee allows a Canadian Generic to get to market faster.
 
            category:news
Empower Pharmacy has challenged the patent on Eli Lilly's Tirzepatide, creating possibly the biggest possible shock to come to compounding GLP1s.
 
            drug:eloralinitide
We dig into early results around Eloralinitide, an amylin-based weight loss formulation being developed by Eli Lilly.
 
            category:side-effects
A critical look at the popular "ozempic penis" claims and look at the sources, along with possible reasons and related research.
company:eli-lilly
We take a look at some exciting upcoming presentations by Eli Lilly about it's old and new GLP1 receptor agonists.
research
Finally, a research clinical trial that directly explores the difference between Semaglutide and Tirzepatide for Obesity.
 
            company:roche
We take a look at Roche (via Carmot)'s GLP1 pipeline development, and figure out how CT-388, CT-996, and CT-868 are trending.
category:news
New study suggests link between GLP1 Receptor Agonists (Ozempic, Mounjaro, etc) and kidney cancer.
malady:addiction
We trace research on GLP1s and addiction through the years and try to find studies that match the anecdotes.